PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Multifocal and Multicentric Breast Carcinoma: A Significantly More Aggressive Tumor than Unifocal Breast Cancer.

Abstract There are still many questions that surround multifocal or multicentric breast carcinoma (MMBC). The aim of this study was to analyze the clinicopathological characteristics of MMBC and provide feasible suggestions for therapy.
PMID
Related Publications

Correlation of tumor volume and surface area with lymph node status in patients with multifocal/multicentric breast carcinoma.

Multicentric and multifocal versus unifocal breast cancer: is the tumor-node-metastasis classification justified?

The importance of multifocal/multicentric tumor on the disease-free survival of breast cancer patients: single center experience.

Evaluation of biomarkers in multifocal/multicentric invasive breast carcinomas.

Pathologic analysis of tumor size and lymph node status in multifocal/multicentric breast carcinoma.

Authors

Mayor MeshTerms
Keywords

ER

HER2

Multifocal and multicentric breast carcinoma

PR

Journal Title anticancer research
Publication Year Start




PMID- 28739757
OWN - NLM
STAT- MEDLINE
DA  - 20170725
DCOM- 20170803
LR  - 20170803
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 37
IP  - 8
DP  - 2017 Aug
TI  - Multifocal and Multicentric Breast Carcinoma: A Significantly More Aggressive
      Tumor than Unifocal Breast Cancer.
PG  - 4593-4598
AB  - BACKGROUND/AIM: There are still many questions that surround multifocal or
      multicentric breast carcinoma (MMBC). The aim of this study was to analyze the
      clinicopathological characteristics of MMBC and provide feasible suggestions for 
      therapy. PATIENTS AND METHODS: A total of 156 cases of MMBC in 3,597 invasive
      ductal breast carcinomas were collected and reviewed. Some factors related with
      prognosis such as tumor size, lymph node metastasis and others were assessed in
      each tumor focus, and mismatches among foci were recorded. RESULTS: The majority 
      of MMBC had aggregate dimensions over 2 cm (85.90%). The rate of axillary lymph
      node metastasis was 56.41% (88/156) compared to unifocal tumors of 33.01%
      (1,136/3,441). Most cases had higher Ki-67 proliferative indices (91/156).
      Mismatches in ER status were present in 6 cases, PR in 4 cases, proliferative
      index (Ki-67) in 9 cases and HER2-positive status in 2 cases. CONCLUSION: The
      larger aggregate dimension of tumor, the higher metastatic rate of axillary lymph
      node and the high Ki-67 proliferative index seen in most cases, suggest that MMBC
      is biologically more aggressive than unifocal breast cancer. In addition, every
      focus should be tested owing to the existence of different expressions of
      immunostaining between foci.
CI  - Copyright(c) 2017, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Lang, Zhiqiang
AU  - Lang Z
AD  - Department of Pathology, Yuhuangding Hospital of Qingdao University, Yantai, P.R.
      China.
FAU - Wu, Yanqiu
AU  - Wu Y
AD  - Department of Medicine, Yuhuangding Hospital of Qingdao University, Yantai, P.R. 
      China.
FAU - Li, Cuiyan
AU  - Li C
AD  - Department of Medicine, Yuhuangding Hospital of Qingdao University, Yantai, P.R. 
      China.
FAU - Li, Xinna
AU  - Li X
AD  - Department of Pathology, Yuhuangding Hospital of Qingdao University, Yantai, P.R.
      China.
FAU - Wang, Xuan
AU  - Wang X
AD  - Department of Medicine, Yuhuangding Hospital of Qingdao University, Yantai, P.R. 
      China [email protected] [email protected]
FAU - Qu, Guimei
AU  - Qu G
AD  - Department of Pathology, Yuhuangding Hospital of Qingdao University, Yantai, P.R.
      China [email protected] [email protected]
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Axilla
MH  - Biomarkers, Tumor
MH  - Breast Neoplasms/genetics/metabolism/*pathology
MH  - Carcinoma/genetics/metabolism/*pathology
MH  - Carcinoma, Ductal, Breast/metabolism/pathology
MH  - Disease Progression
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Lymphatic Metastasis
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Neoplasm Staging
MH  - Tumor Burden
OTO - NOTNLM
OT  - ER
OT  - HER2
OT  - Multifocal and multicentric breast carcinoma
OT  - PR
EDAT- 2017/07/26 06:00
MHDA- 2017/08/05 06:00
CRDT- 2017/07/26 06:00
PHST- 2017/05/19 [received]
PHST- 2017/06/06 [revised]
PHST- 2017/06/07 [accepted]
AID - 37/8/4593 [pii]
PST - ppublish
SO  - Anticancer Res. 2017 Aug;37(8):4593-4598.